Clifford Sloop, NP
Nurse Practitioner · Dothan, ALNPI 1548630452
Payments from drug & device makers
Across 459 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$768
- GSK$538
- AstraZeneca$512
- Pfizer$425
- Bayer$424
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,17298%
- Education$1382%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 94 | $1,296 |
| Lilly USA, LLC | 60 | $768 |
| GSK | 33 | $538 |
| AstraZeneca | 29 | $512 |
| Pfizer | 25 | $425 |
| Bayer | 23 | $424 |
| Amgen | 27 | $351 |
| Novo Nordisk | 25 | $292 |
| Astellas Pharma US Inc | 12 | $278 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $243 |
| Johnson & Johnson | 19 | $225 |
| Corium, LLC | 9 | $213 |
| Otsuka America Pharmaceutical, Inc. | 8 | $173 |
| Abbott | 10 | $171 |
| Boehringer Ingelheim | 10 | $157 |
| Phathom Pharmaceuticals, Inc. | 10 | $155 |
| Genentech USA, Inc. | 1 | $118 |
| Amarin Pharma, Inc. | 6 | $108 |
| Radius Health, Inc. | 4 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $96 |
| Vanda Pharmaceuticals Inc. | 4 | $96 |
| Exact Sciences | 5 | $91 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $72 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Almatica Pharma LLC | 3 | $47 |
| Tandem Diabetes Care, Inc. | 2 | $45 |
| Corcept Therapeutics | 2 | $35 |
| Shield Therapeutics Inc | 2 | $33 |
| Novartis | 2 | $32 |
| Merck | 2 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,310 in reported general payments places this provider in the 95th percentile of 1,505 nurse practitioner providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 156 | $166,007 |
| JardianceEmpagliflozin | 144 | $123,461 |
| EliquisApixaban | 143 | $105,208 |
| OzempicSemaglutide | 96 | $104,352 |
| XareltoRivaroxaban | 103 | $88,092 |
| JanuviaSitagliptin Phosphate | 71 | $60,646 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $47,884 |
| EntrestoSacubitril/Valsartan | 62 | $43,248 |
| KerendiaFinerenone | 59 | $37,986 |
| LinzessLinaclotide | 34 | $35,131 |
| FarxigaDapagliflozin Propanediol | 33 | $27,580 |
| TrulicityDulaglutide | 25 | $23,752 |
| MyrbetriqMirabegron | 30 | $17,362 |
| UbrelvyUbrogepant | 12 | $13,058 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $13,021 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $768 | $193,747201 claims |
| Boehringer IngelheimJardiance, Tradjenta | $157 | $129,887156 claims |
| PfizerEliquis | $425 | $105,208143 claims |
| Novo NordiskOzempic | $292 | $104,35296 claims |
| Johnson & JohnsonXarelto | $225 | $88,092103 claims |
| MerckJanuvia, Janumet Xr, Janumet | $27 | $81,262100 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $538 | $68,499112 claims |
| AbbVieLinzess, Ubrelvy | $1,296 | $48,18946 claims |
| NovartisEntresto | $32 | $43,24862 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $512 | $39,22845 claims |
| BayerKerendia | $424 | $37,98659 claims |
| Astellas Pharma US IncMyrbetriq | $278 | $17,36230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,505 nurse practitioner providers in Alabama.
Other nurse practitioner in Dothan
- Hollie CrutchfieldDothan$22K
- Christina BellDothan$14K
- Shea CalhounDothan$14K
- Amanda PybusDothan$13K
- Tami CaldwellDothan$13K
- Alison HallDothan$12K
- Jennifer ParrishDothan$12K
- Amanda SewellDothan$11K
- Amy EthridgeDothan$11K
- Allison McAllisterDothan$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.